Medtronic Warning Letters Lifted, Clearing Path For CRM, Neurostim PMAs

A barrier to FDA approval for several of Medtronic's core product candidates was lifted with the firm's announcement March 9 that longstanding warning letters had been resolved.

More from Archive

More from Medtech Insight